On October 7, 2020, Hillhouse-backed Genor Biopharma listed on the Hong Kong Stock Exchange. Founded in 2007, Genor focuses on bringing innovative, high-quality oncology and autoimmune therapeutics to meet patient needs. Hillhouse has worked closely with the company to build and refine its capabilities in areas such as talent development, clinical strategy development and manufacturing upgrade.
“Genor BioPharma’s listing on the Hong Kong Stock Exchange marks the beginning of a new chapter in the company’s development. As an innovative biopharmaceutical company, Genor BioPharma has a rich pipeline of innovative drugs under research and a clear commercialization path. Looking forward, we will continue to be a strong partner for Genor BioPharma,” said Michael Yi, Hillhouse Co-CIO.